T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
- PMID: 28280247
- PMCID: PMC6286077
- DOI: 10.1126/science.aaf1292
T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition
Abstract
Programmed cell death-1 (PD-1) is a coinhibitory receptor that suppresses T cell activation and is an important cancer immunotherapy target. Upon activation by its ligand PD-L1, PD-1 is thought to suppress signaling through the T cell receptor (TCR). By titrating PD-1 signaling in a biochemical reconstitution system, we demonstrate that the co-receptor CD28 is strongly preferred over the TCR as a target for dephosphorylation by PD-1-recruited Shp2 phosphatase. We also show that CD28, but not the TCR, is preferentially dephosphorylated in response to PD-1 activation by PD-L1 in an intact cell system. These results reveal that PD-1 suppresses T cell function primarily by inactivating CD28 signaling, suggesting that costimulatory pathways play key roles in regulating effector T cell function and responses to anti-PD-L1/PD-1 therapy.
Copyright © 2017, American Association for the Advancement of Science.
Figures




Comment in
-
T cells: Successful checkpoint blockade requires positive co-stimulation.Nat Rev Immunol. 2017 Mar 27;17(4):215. doi: 10.1038/nri.2017.32. Nat Rev Immunol. 2017. PMID: 28345633 No abstract available.
-
Costimulation, a surprising connection for immunotherapy.Science. 2017 Mar 31;355(6332):1373-1374. doi: 10.1126/science.aan1467. Science. 2017. PMID: 28360282 No abstract available.
-
Two Strings in One Bow: PD-1 Negatively Regulates via Co-receptor CD28 on T Cells.Immunity. 2017 Apr 18;46(4):529-531. doi: 10.1016/j.immuni.2017.04.003. Immunity. 2017. PMID: 28423334
Similar articles
-
PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.Immunity. 2019 Dec 17;51(6):1059-1073.e9. doi: 10.1016/j.immuni.2019.11.003. Epub 2019 Nov 19. Immunity. 2019. PMID: 31757674 Free PMC article.
-
Restriction of PD-1 function by cis-PD-L1/CD80 interactions is required for optimal T cell responses.Science. 2019 May 10;364(6440):558-566. doi: 10.1126/science.aav7062. Epub 2019 Apr 18. Science. 2019. PMID: 31000591
-
Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.J Immunol. 2005 Jun 1;174(11):6648-56. doi: 10.4049/jimmunol.174.11.6648. J Immunol. 2005. PMID: 15905503
-
Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.Adv Exp Med Biol. 2020;1248:33-59. doi: 10.1007/978-981-15-3266-5_3. Adv Exp Med Biol. 2020. PMID: 32185706 Review.
-
Interplay between CD28 and PD-1 in T cell immunotherapy.Vascul Pharmacol. 2025 Mar;158:107461. doi: 10.1016/j.vph.2024.107461. Epub 2024 Dec 27. Vascul Pharmacol. 2025. PMID: 39734005 Review.
Cited by
-
PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy.Front Immunol. 2021 Feb 23;12:636238. doi: 10.3389/fimmu.2021.636238. eCollection 2021. Front Immunol. 2021. PMID: 33708224 Free PMC article. Review.
-
Association of gestational diabetes mellitus and negative modulation of the specific humoral and cellular immune response against Toxoplasma gondii.Front Immunol. 2022 Sep 20;13:925762. doi: 10.3389/fimmu.2022.925762. eCollection 2022. Front Immunol. 2022. PMID: 36203592 Free PMC article.
-
Cbl-b deficiency prevents functional but not phenotypic T cell anergy.J Exp Med. 2021 Jul 5;218(7):e20202477. doi: 10.1084/jem.20202477. Epub 2021 May 11. J Exp Med. 2021. PMID: 33974042 Free PMC article.
-
Bestatin, A Pluripotent Immunomodulatory Small Molecule, Drives Robust and Long-Lasting Immune Responses as an Adjuvant in Viral Vaccines.Vaccines (Basel). 2023 Nov 4;11(11):1690. doi: 10.3390/vaccines11111690. Vaccines (Basel). 2023. PMID: 38006022 Free PMC article.
-
Gamma-Chain Receptor Cytokines & PD-1 Manipulation to Restore HCV-Specific CD8+ T Cell Response during Chronic Hepatitis C.Cells. 2021 Mar 3;10(3):538. doi: 10.3390/cells10030538. Cells. 2021. PMID: 33802622 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials